Prevalence of Secondary Causes of Bone Loss Among Breast Cancer Patients With Osteopenia and Osteoporosis

To determine the prevalence of secondary causes of bone loss among patients with breast cancer with osteopenia and osteoporosis. All women referred to a bone health clinic over a 6-year period for bone evaluation were included in this retrospective study and stratified based on presence or absence o...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of clinical oncology Vol. 26; no. 33; pp. 5380 - 5385
Main Authors:	CAMACHO, Pauline M, DAYAL, Amit S, DIAZ, Josefina L, NABHAN, Fadi A, AGARWAL, Monica, NORTON, John G, ROBINSON, Patricia A, ALBAIN, Kathy S
Format:	Journal Article
Language:	English
Published:	Alexandria, VA American Society of Clinical Oncology 20-11-2008
Subjects:	Aged Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Aromatase Inhibitors - adverse effects Aromatase Inhibitors - therapeutic use Biological and medical sciences Bone Density Bone Diseases, Metabolic - complications Bone Diseases, Metabolic - diagnosis Bone Diseases, Metabolic - etiology Breast Neoplasms - complications Breast Neoplasms - drug therapy Diseases of the osteoarticular system Female Humans Medical sciences Middle Aged Osteoporosis - diagnosis Osteoporosis - etiology Tumors Tumors of striated muscle and skeleton Human Secondary Breast disease Prevalence Diseases of the osteoarticular system Breast cancer Malignant tumor Epidemiology Mammary gland diseases Osteoporosis Bone cancer Cancerology Osteopenia Cancer
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	To determine the prevalence of secondary causes of bone loss among patients with breast cancer with osteopenia and osteoporosis. All women referred to a bone health clinic over a 6-year period for bone evaluation were included in this retrospective study and stratified based on presence or absence of a breast cancer history. The prevalence of secondary causes of bone loss in the two groups was compared. Of the 238 women identified, 64 women had breast cancer. The non-breast cancer group (n = 174) was significantly older (P = .015), had a lower mean weight (P = .019), lower 25 hydroxy-vitamin D level (P = .019), and greater degree of bone loss in both the spine and hip (P < .001 and 0.004, respectively). The presence of at least one secondary cause of bone loss, excluding cancer-related therapies, was seen in 78% of the breast cancer patient group and in 77% of the non-breast cancer group (P = not significant). Newly diagnosed metabolic bone disorders were seen in 58% of the breast cancer population. The most common was vitamin D deficiency, seen in 38% of patients in the breast cancer group and 51% of patients in the non-breast cancer group. Idiopathic hypercalciuria was diagnosed in 15.6%, primary hyperparathyroidism in 1.6%, and normocalcemic hyperparathyroidism in 3.1% of the breast cancer population. A high prevalence of secondary causes of bone loss among patients with breast cancer supports a comprehensive evaluation in these patients, particularly those considering therapy with an aromatase inhibitor.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0732-183X 1527-7755
DOI:	10.1200/JCO.2008.17.7451